CorMedix Inc is a pharmaceutical company based in Bedminster, NJ, specializing in the research, development, and commercialization of therapeutic products for the prevention and treatment of infectious and inflammatory diseases. Their flagship product, DefenCath, has been approved by the U.S. FDA to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in patients receiving hemodialysis.
With a dedicated management team, board of directors, and scientific advisory board, CorMedix is committed to advancing their pipeline of products, including LOCK-IT-100 and taurolidine, through early science research and development. The company also actively engages with investors, media, and the scientific community through publications, presentations, and events, ensuring transparency and corporate governance.
Generated from the website